"Holden Comprehensive Cancer Center is Iowa's only NCI-designated comprehensive cancer center and has held that designation since 2000. The NCI designation recognizes our cancer center, and its research scientists, physicians, and other health care professionals, for their roles in advancing cancer research that impacts on our ability to prevent, detect, and treat our patients with cancer."

During the past decade, University of Iowa/Holden Comprehensive Cancer Center conducted 196 clinical trials. In the 10-year time frame, 196 clinical trials started and 217 clinical trials were completed, i.e. on average, 110.7% percent of trials that started reached the finish line to date. In the past 5 years, 68 clinical trials started and 86 clinical trials were completed. i.e. 126.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Iowa/Holden Comprehensive Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 185 trials, followed by "Children's Oncology Group" with 110 trials sponsored, "Alliance for Clinical Trials in Oncology" with 96 trials sponsored, "Gynecologic Oncology Group" with 64 trials sponsored and "SWOG Cancer Research Network" with 64 trials sponsored. Other sponsors include 141 different institutions and companies that sponsored additional 59 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Iowa/Holden Comprehensive Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 399 trials as a collaborator, "NRG Oncology" with 50 trials as a collaborator, "SWOG Cancer Research Network" with 18 trials as a collaborator, "Cancer and Leukemia Group B" with 14 trials as a collaborator and "Eastern Cooperative Oncology Group" with 13 trials as a collaborator. Other collaborators include 133 different institutions and companies that were collaborators in the rest 72 trials.

According to Clinical.Site data, the most researched conditions in "University of Iowa/Holden Comprehensive Cancer Center" are "Leukemia" (41 trials), "Lymphoma" (34 trials), "Lung Cancer" (24 trials), "Sarcoma" (24 trials) and "Breast Cancer" (22 trials). Many other conditions were trialed in "University of Iowa/Holden Comprehensive Cancer Center" in a lesser frequency.

Most popular intervention types in "University of Iowa/Holden Comprehensive Cancer Center" are "Drug" (487 trials), "Other" (268 trials), "Biological" (201 trials), "Procedure" (159 trials) and "Radiation" (130 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (172 trials), "Quality-of-Life Assessment" (73 trials), "Questionnaire Administration" (56 trials), "Carboplatin" (48 trials) and "Cyclophosphamide" (48 trials). Other intervention names were less common.

The vast majority of trials in "University of Iowa/Holden Comprehensive Cancer Center" are 455 trials for "All" genders, 145 trials for "Female" genders and 25 trials for "Male" genders.

Currently, there are NaN active trials in "University of Iowa/Holden Comprehensive Cancer Center". undefined are not yet recruiting, 87 are recruiting, 154 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 318 completed trials in University of Iowa/Holden Comprehensive Cancer Center, 7 suspended trials, and 45 terminated clinical trials to date.

Out of the total trials that were conducted in University of Iowa/Holden Comprehensive Cancer Center, 60 "Phase 1" clinical trials were conducted, 296 "Phase 2" clinical trials and 227 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 29 trials that are defined as “Not Applicable".